UVA researchers Alban Gaultier (one of our Pharmacology Training Faculty) and Dorian Rosen (one of our Pharmacology Student Alumni) found last year that fluvoxamine may stop the deadly inflammation known as sepsis, in which the immune response spirals out of control. The drug, they determined, reduced the production of cytokines. It proved effective in mice as a preventative treatment for sepsis, and now it will be tested as a protective measure for patients with COVID-19.
Gaultier and Rosen Make Headlines for Discovery of A Potential Treatment for COVID-19
May 19, 2020 by zrb8mf@virginia.edu